期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 62, 期 5, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00026-18
关键词
pharmacokinetics/pharmacodynamics; Pseudomonas aeruginosa; multidrug resistance
资金
- Institute for Clinical Pharmacodynamics (ICPD), Schenectady, NY
- Infectious Pathology and Antimicrobials Research Group (IPAR), Institute Hospital del Mar d' Investigacions Mediques (IMIM)
- ICPD
- Parc de Salut Mar
- Ministerio de Economia y Competitividad of Spain, Instituto de Salud Carlos III
- European Regional Development Fund (ERDF) project A way to achieve Europe through the Spanish Network for Research in Infectious Diseases (REIPI) [RD12/0015, RD16/0016, PI16/00669, PI15/00088]
The aim of this study was to investigate the efficacy of ceftolozanetazobactam in combination with meropenem against an extensively drug-resistant (XDR) Pseudomonas aeruginosa high-risk clone, sequence type 175, isolated in a Spanish university hospital. A 14-day hollow-fiber infection model was used to simulate clinical exposure of the two drug regimens alone and in combination, and serial samples were collected to determine drug concentrations and CFU counts. The untreated control failed, as did each study regimen when administered alone. However, when ceftolozane-tazobactam was administered in combination with meropenem, there was a >4-log(10) CFU/ml bacterial density reduction and suppression of resistance for the duration of the study. These data suggest that ceftolozanetazobactam plus meropenem may be a useful combination for treating XDR P. aeruginosa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据